Pouya Nazari

Pouya Nazari

Auto-generated profile, based on publicly available information

Pouya Nazari

KU Leuven

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in bioRxiv
Verified
Preprint
Open access
PNPouya Nazari
Pouya Nazari
AAAlexandre Arnould
Alexandre Arnould
MAMadhavi Dipak Andhari
Madhavi Dipak Andhari
MFMaite Fontecha
Maite Fontecha
JHJorge Martín Hernández
Jorge Martín Hernández
AAAsier Antoranz
Asier Antoranz
High-dimensional cyclic multiplexed immunofluorescence (cMIF) enables single-cell phenotyping within intact tissues. Cell annotations rely on a multi-step pipeline involving normalization, sampling, dimensionality reduction, and clustering, but the absence of standardized benchmarks for method selection—especially at the clustering stage—leads to inconsistent and less reproducible phenotyping. To address this, we developed CONCLAVE, a consensus-clustering-based workflow that optimizes upstream steps and integrates results from multiple clustering algorithms retaining only those cell labels supported by at least two independent methods. Through in-silico simulations and real-world cMIF datasets, CONCLAVE consistently outperformed single-clustering-method approaches in accuracy, reproducibility, and robustness, with improvements becoming more evident when mapped within spatial tissue contexts. Additionally, CONCLAVE includes a scoring module that flags regions likely to contain unreliable or inconsistent data, facilitating targeted quality control. In summary, CONCLAVE offers a robust framework for cell annotation in cMIF datasets, enhancing the reliability of downstream spatial proteomics analyses. Graphical

19 October 2025 in bioRxiv
Verified
Preprint
Open access
LWLinqian Weng
Linqian Weng
KGKrish Skandha Gopalan
Krish Skandha Gopalan
MGMélanie Guyot
Mélanie Guyot
Maxime VanmechelenMaxime Vanmechelen
Maxime Vanmechelen
PNPouya Nazari
Pouya Nazari
GBGabriele Bergers
Gabriele Bergers
Background: Immunotherapies have improved outcomes in many cancers but show limited efficacy in glioblastoma (GBM). This study aimed to determine whether immunotherapy could be tailored to GBM by functional subtyping of vascular-immune landscapes. Methods: We employed single-cell RNA sequencing, multiplex immunohistochemistry to characterize three distinct TIME subtypes in human and murine GBMs. We evaluated responses to combination of anti-angiogenic immunomodulating therapies (CD40 Ag, anti-PDL1, PI3Kγ/δ inhibition) in orthotopic syngeneic GBM mouse models. Results: We identified three distinct functional TIME subtypes with unique vascular-immune landscapes in human and murine GBM: TIME-low (immune-low/deserted, leaky vasculature), TIME-med (intermediate immune-infiltration, angiogenic), and TIME-high (heavily infiltrated with immunosuppressive myeloid cells and dysfunctional T cells). Representative mouse models of TIME-GBMs responded in subtype specific ways to anti-angiogenic immunomodulating therapies. TIME-low GBMs enhanced T-cell activity but relapsed due to emerging myeloid immunosuppression, concomitant with mesenchymal transition. TIME-med displayed the most immune-activated, yet angiogenic phenotype, and showed overall good responses to various anti-angiogenic immunomodulating therapies. TIME-high GBMs were mostly non-responsive but improved when the myeloid-cell PI3Kγ was targeted. However, CD40 agonist treatment, expected to enhance APC function, unexpectedly worsened survival by promoting angiogenesis and heightening immunosuppression, leading to dysfunctional T cells and reduced NK cell recruitment, and subsequent enhanced tumor propagation. Conclusions: Our study reveals three GBM TIME subtypes with distinct vascular-immune landscapes that require tailored therapies. TIME-med tumors are predicted to respond best to immunotherapies, TIME-low tumors show transient effects with anti-angiogenic immunomodulating therapies, while TIME-high tumors, due to their profound immunosuppression, can even have worse outcomes. Key points: Three TIME subtypes were identified in GBM with distinct vascular-immune landscapes TIME subtypes show divergent immunotherapy responses TIME classification supports personalized treatment strategy for GBM immunotherapy Importance of the Study: This study advances glioblastoma immunotherapy by providing the first comprehensive single-cell characterization of TIME subtypes, moving beyond bulk RNA-sequencing to reveal detailed functional states of immune cells. We establish clinically relevant murine models that recapitulate human TIME subtypes, enabling preclinical testing of TIME-targeted therapies. Our findings identify TIME-low GBM as immune deserted and TIME-med tumors as the most immunotherapy-responsive subtype that should be prioritized for clinical selection. We found that high immune infiltration correlates with non-responsiveness and even unexpected detrimental effects with CD40 agonist treatment in TIME-high tumors—critical information given ongoing clinical trials. Identifying distinct immunosuppressive mechanisms across TIME subtypes and differential treatment responses provides a framework for personalized immunotherapy selection. The immediate translational impact of this work highlights the importance of TIME classification for treatment stratification and the urgent need to consider TIME status in clinical trial design, potentially explaining variable patient responses in previous GBM immunotherapy trials.

25 June 2024 in Research Square
Verified
Preprint
Open access
PDF file
Frederik De SmetFrederik De Smet
Frederik De Smet
Maxime VanmechelenMaxime Vanmechelen
Maxime Vanmechelen
PNPouya Nazari
Pouya Nazari
JBJan Beckervordersandforth
Jan Beckervordersandforth
DLDaphne Leunissen
Daphne Leunissen
AHAnn Hoeben
Ann Hoeben
The authors have requested that this preprint be removed from Research Square.

12 November 2026 in Cell Reports Methods
Verified
Journal Article
Open access
PNPouya Nazari
Pouya Nazari
AAAlexandre Arnould
Alexandre Arnould
MAMadhavi Dipak Andhari
Madhavi Dipak Andhari
MFMaite Fontecha
Maite Fontecha
JMJorge Martín
Jorge Martín
AAAsier Antoranz
Asier Antoranz